[BMY] Bristol Myers Squibb: Q3 2026 earnings preview, Eliquis net price and cash flow

Bristol Myers Squibb, a large U.S. drugmaker focused on oncology, hematology, immunology, cardiovascular and neuroscience medicines, is scheduled to report results for the third quarter of 2026, ending September 30, 2026, and hold its earnings call on 2026-10-29, according to the earnings calendar[1]. In its latest disclosed period, the second quarter of 2026, revenue rose 6% to $12.973 billion; Growth Portfolio revenue rose 15% to $7.560 billion and the anticoagulant Eliquis rose 22% to $4.481 billion, while GAAP EPS was $1.62 and non-GAAP EPS was $2.04[2][3]. With those results, the company raised its 2026 revenue guidance from about $46.0-$47.5 billion to about $49.0-$50.0 billion and its non-GAAP EPS guidance from $6.05-$6.35 to $6.75-$7.00, and it guided to 20%-25% growth in Eliquis and a 4%-6% decline in the Legacy Portfolio for the year[4]. The company gives no quarterly guidance; subtracting first-half revenue of $24.462 billion and non-GAAP EPS of $3.62 from the full-year range implies average second-half quarters of roughly $12.27-$12.77 billion in revenue and $1.57-$1.69 in EPS[5]. The Drillr consensus of 13 analysts puts third-quarter revenue at $12.616 billion, and 15 analysts put EPS at $1.73, above that implied range[6]; because the company's non-GAAP EPS includes Acquired IPRD and a $600 million upfront payment to Hengrui falls in the third quarter, the data cannot show whether that estimate already absorbs the charge[7].

Three things matter most in this Bristol Myers Squibb Q3 2026 earnings preview. First, whether Eliquis keeps pace with its 20%-25% full-year growth guide: after the U.S. list-price cut, rebates fell and realized net price rose, U.S. Eliquis grew 27% in the second quarter, and the company-wide gross-to-net (GTN) deduction rate fell from 46% to 30%, so third-quarter sales and the GTN rate will show whether this is a lasting net-price reset or a one-time accounting shift[8]. Second, whether the Growth Portfolio holds near $7.5 billion a quarter: Revlimid and Pomalyst now face full U.S. generic competition, non-Eliquis Legacy products fell to $942 million in the second quarter, and with Eliquis declining from 2027 the Growth Portfolio has to carry company revenue on its own[9]. Third, whether the revenue raise converts into EPS and cash: the Hengrui upfront payment sits outside full-year guidance, first-half operating cash flow was about $4.5 billion, $1.4 billion below the prior year, and whether third-quarter operating cash flow returns above $5 billion determines how much room the company has to fund R&D, licensing deals and dividends before Eliquis loses exclusivity[10][11].

Company Background and Business Structure

Bristol Myers Squibb is an innovative-medicines company assembled through several large acquisitions, and it now sits between two patent cliffs. The company traces back to a New York business founded in 1887, was incorporated in Delaware in 1933, took its current name after the 1989 merger of Bristol-Myers and Squibb, and operates a single segment covering the discovery, development, licensing, manufacturing and sale of innovative medicines; the 2019 Celgene acquisition brought Revlimid, Pomalyst and CAR-T cell therapy, and in 2024 it acquired Mirati, RayzeBio and Karuna[12]. Revlimid and Pomalyst already face generics, the EU composition-of-matter patents for Eliquis, its largest product, expire in November 2026, settled U.S. generic makers may launch in 2028, and the U.S. composition-of-matter patent for Opdivo also expires in 2028[13].

The company reports product revenue in a Growth Portfolio and a Legacy Portfolio, and the two moved in opposite directions in the second quarter of 2026. Of $12.973 billion in second-quarter revenue, the Growth Portfolio contributed $7.560 billion, or 58.3%, led by Opdivo at $2.485 billion, Orencia at $1.034 billion, Yervoy at $769 million, Reblozyl at $735 million, Breyanzi at $484 million, Camzyos at $416 million, Opdualag at $349 million, subcutaneous Opdivo Qvantig at $261 million and the schizophrenia drug Cobenfy at $63 million[9]. The Legacy Portfolio contributed $5.422 billion, including Eliquis at $4.481 billion, or 34.5% of company revenue, Revlimid at $425 million and Pomalyst at $204 million, the latter two down 49% and 71% year over year[14]. By geography, U.S. revenue was $8.991 billion, about 69% of the total[9].

U.S. revenue is concentrated in a few wholesalers, and the company books revenue net of rebates and discounts. About 97% of gross U.S. revenue ships through wholesalers and specialty distributors, and the three largest, McKesson, Cencora and Cardinal Health, accounted for 36%, 29% and 22% of gross U.S. revenue in 2025, or about 87% combined[15]. In 2025, gross product sales of $88.085 billion became net product sales of $46.756 billion after rebates and discounts, a GTN deduction rate of 47% overall and 53% in the U.S.; Medicaid and Medicare rebates alone totaled $18.010 billion, about 20% of gross sales[16].

Two key partnerships give the company a gross-margin structure unlike a typical drugmaker. BMS discovered Eliquis and co-develops and co-commercializes it with Pfizer, with profits shared equally in most markets; in 2025 the Pfizer profit share recorded in cost of products sold was $6.980 billion against Eliquis revenue of $14.443 billion[17]. BMS sells Opdivo and Qvantig as principal worldwide outside Japan, South Korea and Taiwan, but pays Ono royalties of 4% in North America and 15% elsewhere, and the same terms apply to the nivolumab component of Opdualag[18].

Financial History and Current Position

Total revenue was roughly flat from 2023 to 2025, but its composition was almost entirely replaced. Revenue was $45.006 billion, $48.300 billion and $48.194 billion over the three years, while the Growth Portfolio rose from $19.366 billion to $26.409 billion and the Legacy Portfolio fell from $25.640 billion to $21.785 billion[19]. Over the same period Revlimid fell from $6.097 billion to $2.951 billion and Eliquis rose from $12.206 billion to $14.443 billion, with U.S. Eliquis revenue up 6% and international up 14% in 2025[20].

Large swings in profit came mainly from one-time R&D charges tied to licensing and acquisitions rather than from day-to-day operations. In 2024 the company recognized $13.373 billion of Acquired IPRD, posted a net loss attributable to BMS of $8.948 billion and GAAP diluted EPS of -$4.41; in 2025 Acquired IPRD fell to $3.721 billion, net earnings recovered to $7.054 billion, GAAP EPS was $3.46 and non-GAAP EPS was $6.15[21][22]. SG&A fell 14% to $7.267 billion and R&D fell 11% to $9.951 billion in 2025, and the company said its expanded productivity initiative should deliver about $2.0 billion in annual cost savings by the end of 2027[21][12].

In 2025, operating cash flow funded both the dividend and a large debt reduction. Operating cash flow was $13.860 billion, $15.190 billion and $14.156 billion from 2023 to 2025; in 2025 capital expenditures were $1.311 billion, dividends $5.045 billion and long-term debt repayments $10.940 billion, partly offset by $5.740 billion of new long-term debt[23]. The company issued €5.0 billion of euro-denominated senior notes in November 2025 and spent $9.1 billion of cash in November and December to retire $8.7 billion of debt principal, cutting net debt by $4.4 billion for the year[24].

Revenue and profit strengthened in the first half of 2026, but operating cash flow lagged well behind earnings. First-half revenue rose 4% to $24.462 billion and second-quarter revenue rose 6% to $12.973 billion[9]; the second-quarter non-GAAP gross margin was 71.4%, non-GAAP EPS was $2.04, and first-half non-GAAP EPS totaled $3.62[5]. First-half operating cash flow was about $4.5 billion, $1.4 billion below the prior year, which the company attributed to lower net customer receipts after the Eliquis list-price cut[11]; by quarter, operating cash flow was $6.3 billion in the third quarter of 2025, just $1.1 billion in the first quarter of 2026 and $3.4 billion in the second quarter[25]. At June 30 the company held $11.464 billion of cash and marketable debt securities against about $43.1 billion of short- and long-term debt, for net debt of $31.656 billion, down from $34.043 billion at the end of 2025[26].

Operating Model

Revenue equals each product's volume multiplied by its net price after rebates, plus a small amount of alliance and royalty revenue. About 69% of revenue comes from the U.S., nearly all of it shipped through wholesalers, and net price depends on rebates and discounts negotiated with Medicare, Medicaid and commercial payers[9][15][16]. In the second quarter of 2026, the Growth Portfolio's $7.560 billion relied on new patients for newer drugs and on the shift of Opdivo to a subcutaneous form, Eliquis's $4.481 billion relied on higher net price after the list-price cut and on prescription demand, and the remaining $942 million of older products was being eroded by generics[14][27]. The 10-Q shows that average U.S. net selling prices rose 4% year to date, with net prices rising for both the Growth Portfolio and Eliquis[28].

Non-GAAP profit equals revenue multiplied by gross margin, minus SG&A and R&D, minus irregular licensing charges. The second-quarter non-GAAP gross margin was 71.4%, and cost of products sold includes the Eliquis profit share paid to Pfizer and the royalties paid to Ono; payments to alliance partners recorded in cost of products sold were $2.206 billion in the quarter versus $1.827 billion a year earlier[29]. Second-quarter non-GAAP SG&A was $1.826 billion and R&D $2.316 billion, about 14.1% and 17.9% of revenue, Acquired IPRD was zero, and non-GAAP pretax earnings of $4.994 billion at a 16.5% tax rate produced EPS of $2.04[5]. GAAP profit also deducts specified items such as $437 million of intangible amortization in the quarter, which is why GAAP EPS was $1.62[5].

Beyond profit, the largest swing factor in operating cash flow is the change in rebate liabilities. After the list-price cut, Eliquis rebates accrued under the old list price are being paid out in cash, and the balance-sheet liability for rebates and discounts fell from $8.844 billion at the end of 2025 to $5.654 billion at June 30, 2026, which is why first-half operating cash flow was $1.4 billion lower; over the same period the company paid $2.6 billion of dividends and still reduced net debt by $2.4 billion[11]. Upfront and milestone payments on licensing deals are paid in cash and expensed when incurred, and the $600 million Hengrui upfront payment in the third quarter falls into that category[7].

Each driver reaches the financial statements with a different lag. A list-price cut shows up in revenue in the same quarter, but its cash-flow drag fades only once the old rebate liabilities are paid down; because half of Eliquis profit goes to Pfizer, a stronger Eliquis lifts revenue while diluting gross margin, which the company's 69%-70% full-year gross-margin guide attributes to product mix[17][4]. New launches and label expansions usually take several quarters to show up in revenue, while the loss of exclusivity for Eliquis and Opdivo will hit revenue and profit directly in 2027-2028[30][13].

Industry and Competitive Position

Bristol Myers Squibb is one of the world's large pharmaceutical companies, and its competitive position rests on a handful of category-leading products. Revenue was $48.194 billion in 2025[19]; Eliquis is an oral Factor Xa inhibitor co-marketed with Pfizer to reduce stroke risk in nonvalvular atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism, while Cobenfy is an oral schizophrenia drug that acts on M1/M4 muscarinic receptors[20]. In oncology, Opdivo, Yervoy and Opdualag form the main immunotherapy franchise, and management says Opdualag remains the global standard of care in first-line melanoma; hematology includes Reblozyl and Breyanzi, and in cardiovascular, Camzyos treats obstructive hypertrophic cardiomyopathy[31].

The company's future competitiveness depends on whether late-stage pipeline assets can replace Eliquis and Opdivo in 2027-2028. Management says the next-generation anticoagulant milvexian targets the roughly 40% of eligible U.S. atrial fibrillation patients who are undertreated, underdosed or off anticoagulation, that the trial is designed to show efficacy no worse than Eliquis with better bleeding outcomes, and that its expected launch lines up with the 2028 Eliquis loss of exclusivity[32]. In hematology, the oral CELMoD drugs iberdomide and mezigdomide have FDA target action (PDUFA) dates of August 17, 2026 and May 13, 2027, and management expects them to replace Revlimid and Pomalyst in leading second-line multiple myeloma regimens over time; interim Phase II results from the ROSETTA Lung-02 study of pumitamig and interim results from two Phase III studies of iza-bren in China were also positive[33]. Among launched newer drugs, Camzyos has U.S. patent protection to 2036, and Cobenfy's U.S. combination patents run to 2030, or 2033 if a pending extension is granted[13].

U.S. drug-pricing policy and limited peer data mark two boundaries on any judgment of competitive position. IRA government price setting has covered Eliquis in the U.S. Medicare channel since January 1, 2026, Pomalyst follows from 2027, and Orencia has been selected for negotiated prices beginning in 2028[34]; the company's agreement with the U.S. government provides tariff relief until January 2029 and shields it from future U.S. pricing mandates while in effect, but those exemptions may be terminated or not extended[35]. Management also cautioned that new launches in areas such as pulmonary fibrosis and schizophrenia face recently approved incumbent products[36]. The available materials contain no peer financial data, so the company's share or margin position relative to peers cannot be quantified.

Core Debates

After the U.S. list-price cut lifted Eliquis's realized net price, can third-quarter sales keep pace with the full-year guide of 20%-25% growth?

Eliquis is the company's largest single product, and the second half of 2026 is the last window to observe it at peak. Second-quarter Eliquis revenue was $4.481 billion, 34.5% of company revenue, including $3.357 billion in the U.S., up 27%, and $1.124 billion internationally, up 9%[3]. The company has flagged a $1.5-$2 billion decline in Eliquis revenue in 2027, as European exclusivity ends in the fourth quarter of 2026 and U.S. exclusivity ends in April 2028[30]. On the 2025 base of $14.443 billion, 20%-25% growth implies 2026 Eliquis revenue of roughly $17.3-$18.1 billion, of which $8.617 billion was booked in the first half[4][9].

The case for durable growth rests on the rebate shift and share gains. The 10-Q explains that the company cut the U.S. list price of Eliquis in 2026, lowering rebates and raising realized net price; in the second quarter gross product sales fell from $22.181 billion to $18.179 billion, Medicaid and Medicare rebates fell from $4.516 billion to $1.759 billion, and the company-wide GTN rate fell from 46% to 30%[8]. On the call, management attributed Eliquis growth to continued U.S. share gains and kept the 20%-25% full-year growth guide after the second quarter[31]. The alternative reading is that part of the growth reflects a one-time reset in rebate accounting rather than lasting demand, and because IRA Medicare price setting also took effect in January 2026, it is uncertain whether the higher net price will hold in every quarter of the year[34].

The financial transmission runs in three layers: the U.S. list-price cut lowers rebates and raises realized net price, which together with prescription share gains lifts Eliquis revenue; half of that revenue goes to Pfizer as profit share, diluting gross margin; and paying down old rebate liabilities makes cash flow lag revenue[17][11]. The second-quarter non-GAAP gross margin of 71.4% was above the 69%-70% full-year guide, which means the company's own full-year range implies a lower second-half gross margin than in the second quarter[5][4]. What remains unresolved is the split between volume and price: the company does not disclose Eliquis prescriptions or net price, and the company-wide GTN rate and rebate liability include all products, so they serve only as proxies for the list-price effect.

In the third quarter, watch whether global Eliquis revenue is at least about $4.5 billion, whether U.S. growth stays above 20%, whether the company-wide GTN rate holds near 30%, and whether the non-GAAP gross margin stays within the 69%-70% full-year guide. Whether international Eliquis has already begun to fall before European patent expiry will also signal the starting point for the 2027 decline. A stable GTN rate with U.S. growth still above 20% would indicate a lasting net-price reset; Eliquis below $4.35 billion with a cut to the full-year growth guide, or a GTN rate back above 35%, would falsify the current understanding.

As generics rapidly erode Revlimid and Pomalyst, can Reblozyl, Breyanzi, Camzyos and other new medicines keep the Growth Portfolio above roughly $7.5 billion a quarter in the third quarter?

Excluding Eliquis, whether company revenue holds steady depends on a race between the Growth Portfolio and erosion of older products. In 2025 the Growth Portfolio added about $3.8 billion while the Legacy Portfolio lost about $4.0 billion, leaving total revenue roughly flat[19]. Non-Eliquis Legacy products fell to $942 million in the second quarter, about $1.05 billion below the prior year, while Reblozyl, Breyanzi, Camzyos and Cobenfy together added only about $490 million[9]. Guiding to a 4%-6% full-year Legacy decline alongside 20%-25% Eliquis growth implies that non-Eliquis older products keep shrinking sharply in the second half[4].

The case for a durable Growth Portfolio is breadth of growth and a raised guide. In the second quarter the Growth Portfolio grew 15% to 58.3% of revenue, with Reblozyl up 29%, Breyanzi up 41% and Camzyos up 60%[3]; management said ten products across the company grew by double digits[37] and cited broad-based momentum across the portfolio when it raised full-year revenue guidance to $49.0-$50.0 billion[4]. The alternative reading is that the roughly $1.3 billion jump from the first quarter's $6.227 billion partly reflects a seasonally weak first quarter[38]; the newer drugs are still small in absolute terms, Cobenfy brought in only $63 million in the quarter, and top-line results from its Alzheimer's disease psychosis program have slipped to early 2027[37].

The financial transmission is a two-line race: new patients and label expansions for newer drugs lift Growth Portfolio revenue, while U.S. Revlimid generics stopped being volume-limited on January 31, 2026 and U.S. Pomalyst generics launched in March 2026, pushing non-Eliquis Legacy products down[13][14]. The gap between the two decides whether revenue excluding Eliquis can stabilize. From the first quarter to the second, Reblozyl rose from $555 million to $735 million, Breyanzi from $411 million to $484 million and Camzyos from $314 million to $416 million[38][9]. What remains unresolved is that mature products such as Orencia, Yervoy and Opdualag make up about a fifth of company revenue, so the stability of the Growth Portfolio total does not rest on newer drugs alone, and Orencia faces government price setting from 2028.

In the third quarter, watch whether the Growth Portfolio is at least about $7.5 billion, whether Reblozyl, Breyanzi and Camzyos all keep growing sequentially, whether non-Eliquis Legacy products fall meaningfully from $942 million, and whether the company raises full-year revenue guidance again. Management said on the second-quarter call that Revlimid revenue remained resilient despite full U.S. generic availability, so whether that line accelerates its decline in the third quarter is also worth checking[31]. A Growth Portfolio below $7.3 billion, or sequential declines in two or more of the main newer drugs, would falsify the view that newer medicines can replace the older ones.

As intravenous Opdivo declines in the U.S., can subcutaneous Opdivo Qvantig absorb those patients and keep the nivolumab franchise growing before U.S. patent expiry in 2028?

Opdivo and subcutaneous Qvantig together form the company's largest franchise after Eliquis. Combined second-quarter revenue was $2.746 billion, 21.2% of company revenue, while U.S. intravenous Opdivo revenue fell 6% to $1.417 billion[3]; the 10-Q attributes the lower U.S. demand explicitly to greater use of Qvantig[27]. If the switch merely moves patients between formulations, combined revenue will stall, and Qvantig's U.S. exclusivity also rests on the nivolumab composition-of-matter patent that expires in 2028, after which the franchise faces biosimilars[13].

The case for continued franchise growth is the acceleration in combined revenue. Combined second-quarter revenue rose 6.0% from $2.590 billion a year earlier, and Qvantig rose from $163 million in the first quarter to $261 million[38], which management said on the call puts it on an annualized run rate above $1 billion[31]. The alternative reading is that combined first-quarter revenue of $2.309 billion grew only about 1.5% year over year, and the 10-Q notes that first-half U.S. results reflected changes in channel inventory and the timing of customer orders, so part of the second-quarter improvement may be timing[27].

The financial transmission is that U.S. hospitals and clinics move patients from intravenous Opdivo to subcutaneous Qvantig, so intravenous revenue falls and subcutaneous revenue rises, and the combined total sets the size of the immuno-oncology franchise before it loses U.S. composition-of-matter protection. Second-quarter U.S. Qvantig revenue was $206 million, about 12.7% of U.S. nivolumab revenue[3]; both formulations carry the same 4% Ono royalty in North America, so the switch itself does not change the royalty burden per dollar of sales[18]. Opdivo generated $10.049 billion and Qvantig $238 million in 2025, and on the first-quarter call the company reported Qvantig revenue of $163 million[19][39]. What remains unresolved is whether the switch expands the patient base or only changes the formulation for existing patients.

In the third quarter, watch whether combined revenue is at least about $2.75 billion, whether Qvantig keeps growing sequentially toward roughly $300 million, and whether the decline in U.S. intravenous Opdivo is smaller than Qvantig's gain. Combined revenue below $2.65 billion, or a sequential decline in Qvantig, would falsify the view that subcutaneous conversion can keep the franchise growing.

After the revenue raise, how much will launch and R&D spending, the third-quarter Hengrui upfront payment and the run-off of old Eliquis rebates dilute earnings per share and operating cash flow?

The raised EPS guidance excludes a large third-quarter licensing charge, and cash flow has clearly trailed earnings. The $6.75-$7.00 full-year non-GAAP EPS guide excludes Acquired IPRD and licensing income incurred after June 30[10]; in May the company signed global collaboration and license agreements with Hengrui covering 13 early-stage oncology, hematology and immunology assets, under which it will pay $600 million upfront in the third quarter, a $175 million anniversary payment in 2027, possibly a second $175 million in 2028, and up to $14.3 billion in contingent milestones[7]. Dividends payable stood at $1.288 billion on the balance sheet, or roughly $1.29 billion of dividends a quarter, and net debt was $31.656 billion at June 30[11][26].

The case for healthy earnings conversion is first-half progress. Second-quarter non-GAAP EPS was $2.04 and first-half EPS $3.62, already more than half of the midpoint of the full-year guide[5]; second-quarter operating cash flow recovered to $3.4 billion[25], and net debt fell $2.4 billion in the first half[11]. The alternative reading is that second-quarter margins benefited from peak Eliquis, that the company's own full-year guide implies only $1.57-$1.69 of EPS per second-half quarter, and that full-year operating expenses were raised from about $16.3 billion to about $16.5 billion[4]; the second quarter also included a $220 million priority review voucher recorded as R&D expense[7]. Whether weak operating cash flow is only a transition in rebate accounting depends on whether rebate liabilities stabilize in the third quarter.

The financial transmission can be written as revenue times gross margin, minus R&D and selling expenses, one-time licensing charges and tax, which yields non-GAAP EPS; the run-off of old Eliquis rebate liabilities and lower customer receipts keep operating cash flow below earnings until rebate liabilities stabilize. A year earlier, in the second quarter of 2025, about $1.5 billion of Acquired IPRD cut non-GAAP EPS by $0.57 to just $1.46[5], which shows that a single licensing charge can change a quarter's reading. First-half non-GAAP operating expenses totaled about $8.0 billion, so the roughly $16.5 billion full-year guide implies about $4.25 billion a quarter in the second half, slightly above the second quarter's $4.142 billion[4]; the roughly $2.0 billion of annual savings from the productivity initiative will not be fully realized until the end of 2027[33].

In the third quarter, watch whether non-GAAP EPS excluding Acquired IPRD is at least about $1.57, whether reported Acquired IPRD matches the $600 million Hengrui upfront payment, whether non-GAAP operating expenses run near $4.25 billion a quarter, whether operating cash flow returns above $5 billion, and whether rebate liabilities stop falling. EPS excluding IPRD below $1.55, or operating cash flow below $4 billion, would falsify the view that the revenue raise converts smoothly into earnings and cash.

Risks and Falsifiers

U.S. drug-pricing policy is the first risk running across the whole portfolio. IRA price setting has covered Eliquis in the Medicare channel since January 2026, Pomalyst follows from 2027, and Orencia has been selected for negotiated prices starting in 2028; the company's agreement with the U.S. government provides tariff relief and protection from future pricing mandates until January 2029, but those exemptions may be terminated or not extended[34][35]. The exposed lines are Orencia revenue, $3.705 billion in 2025 and $1.034 billion in the second quarter of 2026, and overall rebate levels, with Medicaid and Medicare rebates totaling $18.010 billion in 2025, about 20% of gross sales[19][16]. If the third-quarter report discloses no revenue impact from new government pricing or rebate policy and the GTN rate holds near 30%, this risk did not materialize in the quarter.

The late-stage pipeline meant to replace Eliquis and Opdivo could be delayed or fail. The milvexian atrial fibrillation readout slipped to the first quarter of 2027 because events accrued more slowly than expected, the Cobenfy Alzheimer's disease psychosis readouts slipped to early 2027, and several pivotal readouts, including pulmonary fibrosis, lupus and milvexian in secondary stroke prevention, are still due by the end of 2026[37][36]. The exposure is the revenue base of Eliquis plus Opdivo and Qvantig, about $7.227 billion in the second quarter or roughly 56% of company revenue, both of which lose U.S. exclusivity around 2028[9]. If the key readouts due by the end of 2026 meet their primary endpoints and the company keeps its 2027 readout timetable, this risk would recede materially.

The end of Eliquis exclusivity is the risk with the most certain timing. The EU composition-of-matter patents and supplementary protection certificates expire in November 2026, and generics have already launched early in some European countries; settled U.S. generic makers may launch in 2028, which the call placed in April 2028, and the company has flagged a $1.5-$2 billion decline in Eliquis revenue in 2027[13][30]. Because BMS keeps only half the profit, the profit impact of lost revenue is roughly half the revenue decline, plus related selling costs[17]. If international Eliquis still grows year over year in the third quarter and the company keeps its 2027 step-down of $1.5-$2 billion unchanged in the third-quarter report, European erosion is not running ahead of the company's existing view.

Generic erosion of older products could outpace the ramp of newer drugs. U.S. Revlimid generics stopped being volume-limited on January 31, 2026, U.S. Pomalyst generics launched in March 2026, and the label-expansion studies for Cobenfy have slipped into 2027[14][37]. The exposure is non-Eliquis Legacy revenue, $942 million in the second quarter, about $1.05 billion below a year earlier, while Reblozyl, Breyanzi, Camzyos and Cobenfy together added only about $490 million[9]. If the Growth Portfolio's year-over-year gain in the third quarter still exceeds the year-over-year decline in non-Eliquis Legacy products and full-year revenue guidance is not cut, this risk did not materialize.

Loss of exclusivity for the nivolumab franchise is the second large patent cliff. The composition-of-matter patent expires in 2028 in the U.S. and 2030 in the EU, Qvantig's exclusivity rests on the same patent without counting pending applications, and Ono collects royalties of 4% in North America and 15% elsewhere[13][18]. The exposure is Opdivo revenue of $10.049 billion and Qvantig revenue of $238 million in 2025, and combined second-quarter revenue of $2.746 billion, 21.2% of the company total[19][9]. If the company discloses a patent that extends Qvantig's exclusivity, or combined revenue keeps growing year over year in the third quarter, the timing or size of this risk would ease.

One-time charges from licensing deals are hard to predict. Management lists business development among its capital-allocation priorities, and Acquired IPRD is expensed in the quarter a deal is signed or a milestone is reached, outside full-year guidance[32][10]. The exposure is GAAP and non-GAAP EPS: Acquired IPRD was $3.721 billion in 2025, and the Hengrui deal carries a $600 million upfront payment in the third quarter plus up to $14.3 billion in contingent milestones[21][7]. If third-quarter Acquired IPRD does not exceed $800 million and full-year EPS guidance is adjusted only for disclosed deals, this risk stays within an explainable range for the quarter.

What to Watch Next

The third-quarter checkpoints for the four core debates, each measured against second-quarter or June 30, 2026 disclosures:

• Eliquis after the list-price cut: global revenue against $4.481 billion, with at least about $4.5 billion supportive and below $4.35 billion plus a cut to the growth guide falsifying; U.S. growth against 27%, where staying above 20% with a stable GTN rate points to a lasting net-price reset; the company-wide GTN rate against 30%, where a return above 35% falsifies; and the non-GAAP gross margin against 71.4%, where a figure below 69% would miss the full-year guide.
• Growth Portfolio versus generic erosion: Growth Portfolio revenue against $7.560 billion, falsified below $7.3 billion; Reblozyl, Breyanzi and Camzyos against $735 million, $484 million and $416 million, falsified if two or more fall sequentially; and non-Eliquis Legacy products against $942 million, falsified if the Growth Portfolio's year-over-year gain falls short of their year-over-year decline.
• Opdivo subcutaneous conversion: combined Opdivo and Qvantig revenue against $2.746 billion, falsified below $2.65 billion; Qvantig against $261 million, with growth toward about $300 million supportive and a sequential decline falsifying.
• EPS and cash: non-GAAP EPS excluding IPRD against $2.04, falsified below $1.55; Acquired IPRD against zero, where more than $800 million would exceed disclosed deals; operating cash flow against $3.4 billion, with a return above $5 billion supportive and below $4 billion falsifying; and the rebate and discount liability against $5.654 billion, where a continued steep decline would show rebate payouts still weighing on cash flow.

Conclusion

Bristol Myers Squibb's business is currently driven by three forces: Eliquis, still at peak after the list-price cut; a Growth Portfolio carrying revenue through generic erosion; and an Opdivo franchise shifting from intravenous to subcutaneous use. Second-quarter 2026 revenue rose 6% to $12.973 billion, non-GAAP EPS was $2.04, and full-year guidance was raised to $49.0-$50.0 billion of revenue and $6.75-$7.00 of EPS[2][4]; yet first-half operating cash flow was $1.4 billion below the prior year and net debt still stood at $31.656 billion[11][26]. The central unresolved relationship is how much of the Eliquis growth from the list-price cut will last, whether the Growth Portfolio can hold up revenue on its own before Eliquis declines in 2027, and whether that revenue converts into earnings and cash that are not diluted by licensing charges and rebate payouts.

Since the second-quarter report, only one independent analysis with a clear argument could be found, so outside interpretation is thin and should not be read as a broad market view. Chris Lange of 24/7 Wall St. argues that dividend safety should be judged on cash rather than earnings: 2025 operating cash flow of $14.156 billion less $1.311 billion of capital expenditures comfortably covered $5.045 billion of dividends, but first-quarter 2026 operating cash flow of $1.104 billion fell short of the $1.283 billion quarterly dividend before rebounding to $3.393 billion in the second quarter[40]. He warns that a $1.5-$2 billion Eliquis step-down in 2027 coupled with a failed or delayed milvexian result would push annual operating cash flow net of capital expenditures toward the roughly $5.045 billion dividend bill[40]. His view bears directly on the debates over converting revenue into EPS and cash and over the Eliquis list-price cut: he treats the weak first-quarter cash flow as a coverage risk, while the company's 10-Q attributes the first-half cash shortfall to the transitional payout of rebates after the price cut[11], and the third quarter will test which explanation holds.

The combination that would materially strengthen the current understanding is third-quarter Eliquis of at least about $4.5 billion with a GTN rate steady near 30%, a Growth Portfolio holding near $7.5 billion with the three main newer drugs still growing sequentially, combined Opdivo and Qvantig of at least about $2.75 billion, EPS excluding Acquired IPRD of at least about $1.57, and operating cash flow back above $5 billion alongside stabilizing rebate liabilities. Conversely, Eliquis below $4.35 billion or a GTN rate back above 35%, a Growth Portfolio below $7.3 billion and operating cash flow below $4 billion, combined with failed key pipeline readouts at year-end, would significantly weaken the view that the company can sustain revenue and cash between its two patent cliffs.

Sources

[1] Drillr earnings calendar (updated 2026-09-30) · BMY 2026-10-29 call · 2026-09-30 · Drillr earnings calendar · https://gateway.drillr.ai/mcp/private

[2] BMY 8-K filed 2026-07-30 · Q2 2026 results highlights · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[3] BMY 8-K filed 2026-07-30 · Q2 2026 product revenues U.S. and international · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[4] BMY 8-K filed 2026-07-30 · 2026 guidance update · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[5] BMY 8-K filed 2026-07-30 · Q2 2026 GAAP to non-GAAP reconciliation · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[6] Drillr analyst_financial_estimates (updated 2026-09-30) · BMY quarter ending 2026-09-30 · 2026-09-30 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[7] BMY 10-Q filed 2026-07-30 · Hengrui license and priority review voucher · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[8] BMY 10-Q filed 2026-07-30 · GTN adjustments Q2 2026 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[9] BMY 10-Q filed 2026-07-30 · Q2 2026 revenue by product · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[10] BMY 8-K filed 2026-07-30 · 2026 guidance exclusions · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[11] BMY 10-Q filed 2026-07-30 · operating cash flow and rebate accruals H1 2026 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[12] BMY 10-K filed 2026-02-11 · company overview and productivity initiative · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[13] BMY 10-K filed 2026-02-11 · market exclusivity of key products · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[14] BMY 10-Q filed 2026-07-30 · Eliquis, Revlimid and Pomalyst revenue drivers · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[15] BMY 10-K filed 2026-02-11 · wholesaler concentration · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[16] BMY 10-K filed 2026-02-11 · GTN adjustments FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[17] BMY 10-K filed 2026-02-11 · Pfizer Eliquis alliance profit sharing · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[18] BMY 10-K filed 2026-02-11 · Opdivo royalties to Ono · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[19] BMY 10-K filed 2026-02-11 · revenue by product FY2023-FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[20] BMY 10-K filed 2026-02-11 · Eliquis and Cobenfy revenue drivers FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[21] BMY 10-K filed 2026-02-11 · expenses FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[22] BMY 10-K filed 2026-02-11 · GAAP and non-GAAP EPS FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[23] BMY 10-K filed 2026-02-11 · cash flows FY2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[24] BMY 10-K filed 2026-02-11 · liquidity and net debt 2025 · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[25] BMY 8-K filed 2026-07-30 · operating cash flow and capital allocation · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm

[26] BMY 10-Q filed 2026-07-30 · net debt June 30 2026 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[27] BMY 10-Q filed 2026-07-30 · Opdivo and Opdivo Qvantig revenue drivers · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[28] BMY 10-Q filed 2026-07-30 · U.S. revenue and net price · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[29] BMY 10-Q filed 2026-07-30 · alliance payments Q2 2026 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[30] BMY Q2 2026 earnings call 2026-07-30 · guidance and Eliquis 2027 step-down · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[31] BMY Q2 2026 earnings call 2026-07-30 · segment performance · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[32] BMY Q2 2026 earnings call 2026-07-30 · Milvexian, BD and CELMoD Q&A · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[33] BMY 10-Q filed 2026-07-30 · 2026 pipeline and productivity progress · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[34] BMY 10-K filed 2026-02-11 · IRA Medicare price setting · 2026-02-11 · 10-K · https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/

[35] BMY 10-Q filed 2026-07-30 · IRA and U.S. government agreement · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/

[36] BMY Q2 2026 earnings call 2026-07-30 · stated risks · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] BMY Q2 2026 earnings call 2026-07-30 · pipeline timelines · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[38] BMY 10-Q filed 2026-04-30 · Q1 2026 revenue by product · 2026-04-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/14272/000001427226000010/

[39] BMY Q1 2026 earnings call 2026-04-30 · guidance and Qvantig · 2026-04-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[40] 24/7 Wall St. 2026-09-30 · Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric · 2026-09-30 · 24/7 Wall St. · https://247wallst.com/investing/2026/09/30/bristol-myers-squibbs-dividend-sustainability-hinges-on-one-critical-cash-flow-metric/